Article: A synopsis of current haemophilia care in Hong Kong

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleA synopsis of current haemophilia care in Hong Kong
AuthorsAu, WY8
Lee, V5
Kho, B
Ling, ASC3
Chan, D7
Chan, EYT1
Chan, GCF8
Cheung, WWW8
Lau, CW2
Lee, CY9
Li, RCH2
Li, CK5
Lin, SY7
Mak, V3
Sun, L6
Wong, KHF4
Wong, R5
Yau, J4
Yuen, HL4
KeywordsFactor VIII
Hemophilia A
HIV infections
Mutation
Survival rate
Issue Date2011
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
CitationHong Kong Medical Journal, 2011, v. 17 n. 3, p. 189-194 [How to Cite?]
AbstractObjective To provide a synopsis of current haemophilia care in Hong Kong. Design Retrospective survey. Setting All haematology units of the Hospital Authority in Hong Kong. Patients All patients with haemophilia A and haemophilia B. Results To date, there were 222 mild-to-severe haemophilia patients (192 type A, 30 type B) under regular public care in Hong Kong (43% were considered severe, 33% moderate, and 24% mild), which gave a crude prevalence of 6.8/100 000 male inhabitants. A total of 12.8 million units of Factor VIII and 3 million units of Factor IX were prescribed annually. This amounts to 1.83 units of FVIII per capita of the population, which is comparable to that of other developed countries. Leading causes of mortality were human immunodefciency virus-related complications (10 cases) and cerebral bleeding (2 cases). The life expectancy of patients with severe haemophilia in Hong Kong is improving; currently the oldest patient is 60 years old. Such improved survival may be due to enhanced factor availability, prompt treatment of bleeding episodes at home, safer factor products, and better antiviral treatment. Primary prophylaxis is the accepted standard of care for severe and moderate cases, and "Factor First" has become hospital policy. However, 12 patients continue to present treatment challenges, due to the documented presence of factor inhibitors. In all, 28,100, and 14 cases respectively were positive for human immunodefciency virus, hepatitis C virus, and hepatitis B virus; the youngest patients with the corresponding infections being 28,13, and 22 years old. Comprehensive care with dedicated physiotherapy, surgical support, and radionucleotide synovectomy may reduce morbidity further. Conclusion A multidisciplinary approach can further improve the future care for haemophilia patients in Hong Kong.
DescriptionAuthor Chinese names: WY Au 區永仁, Vincent Lee 李偉生, Bonnie Kho 許紫珊, Alvin SC Ling 凌紹祥, Desmond Chan 陳振榮, Eric YT Chan 陳日東, Godfrey CF Chan 陳志峯, Winnie WW Cheung 張永慧, CW Lau 劉靜華, CY Lee 李靜賢, Rever CH Li 李澤荷, CK Li 李志光, SY Lin 連錫營, Vivien Mak 麥慧敏, Lina Sun 孫偉芬, Kris HF Wong 黃鴻勳, Raymond Wong 王紹明, Jeffrey Yau 丘炳華, HL Yuen 袁煦樑
ISSN1024-2708
2011 SCImago Journal Rankings: 0.054
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorAu, WY
dc.contributor.authorLee, V
dc.contributor.authorKho, B
dc.contributor.authorLing, ASC
dc.contributor.authorChan, D
dc.contributor.authorChan, EYT
dc.contributor.authorChan, GCF
dc.contributor.authorCheung, WWW
dc.contributor.authorLau, CW
dc.contributor.authorLee, CY
dc.contributor.authorLi, RCH
dc.contributor.authorLi, CK
dc.contributor.authorLin, SY
dc.contributor.authorMak, V
dc.contributor.authorSun, L
dc.contributor.authorWong, KHF
dc.contributor.authorWong, R
dc.contributor.authorYau, J
dc.contributor.authorYuen, HL
dc.date.accessioned2011-07-27T01:33:44Z
dc.date.available2011-07-27T01:33:44Z
dc.date.issued2011
dc.description.abstractObjective To provide a synopsis of current haemophilia care in Hong Kong. Design Retrospective survey. Setting All haematology units of the Hospital Authority in Hong Kong. Patients All patients with haemophilia A and haemophilia B. Results To date, there were 222 mild-to-severe haemophilia patients (192 type A, 30 type B) under regular public care in Hong Kong (43% were considered severe, 33% moderate, and 24% mild), which gave a crude prevalence of 6.8/100 000 male inhabitants. A total of 12.8 million units of Factor VIII and 3 million units of Factor IX were prescribed annually. This amounts to 1.83 units of FVIII per capita of the population, which is comparable to that of other developed countries. Leading causes of mortality were human immunodefciency virus-related complications (10 cases) and cerebral bleeding (2 cases). The life expectancy of patients with severe haemophilia in Hong Kong is improving; currently the oldest patient is 60 years old. Such improved survival may be due to enhanced factor availability, prompt treatment of bleeding episodes at home, safer factor products, and better antiviral treatment. Primary prophylaxis is the accepted standard of care for severe and moderate cases, and "Factor First" has become hospital policy. However, 12 patients continue to present treatment challenges, due to the documented presence of factor inhibitors. In all, 28,100, and 14 cases respectively were positive for human immunodefciency virus, hepatitis C virus, and hepatitis B virus; the youngest patients with the corresponding infections being 28,13, and 22 years old. Comprehensive care with dedicated physiotherapy, surgical support, and radionucleotide synovectomy may reduce morbidity further. Conclusion A multidisciplinary approach can further improve the future care for haemophilia patients in Hong Kong.
dc.description.naturepublished_or_final_version
dc.descriptionAuthor Chinese names: WY Au 區永仁, Vincent Lee 李偉生, Bonnie Kho 許紫珊, Alvin SC Ling 凌紹祥, Desmond Chan 陳振榮, Eric YT Chan 陳日東, Godfrey CF Chan 陳志峯, Winnie WW Cheung 張永慧, CW Lau 劉靜華, CY Lee 李靜賢, Rever CH Li 李澤荷, CK Li 李志光, SY Lin 連錫營, Vivien Mak 麥慧敏, Lina Sun 孫偉芬, Kris HF Wong 黃鴻勳, Raymond Wong 王紹明, Jeffrey Yau 丘炳華, HL Yuen 袁煦樑
dc.identifier.citationHong Kong Medical Journal, 2011, v. 17 n. 3, p. 189-194 [How to Cite?]
dc.identifier.epage194
dc.identifier.hkuros187929
dc.identifier.issn1024-2708
2011 SCImago Journal Rankings: 0.054
dc.identifier.issue3
dc.identifier.pmid21636866
dc.identifier.scopuseid_2-s2.0-79958745818
dc.identifier.spage189
dc.identifier.urihttp://hdl.handle.net/10722/135337
dc.identifier.volume17
dc.languageeng
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
dc.publisher.placeHong Kong
dc.relation.ispartofHong Kong Medical Journal
dc.relation.referencesReferences in Scopus
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
dc.subject.meshCoagulants - therapeutic use
dc.subject.meshFactor IX - therapeutic use
dc.subject.meshFactor VIII - therapeutic use
dc.subject.meshHemophilia A - epidemiology - physiopathology - therapy
dc.subject.meshHemophilia B - epidemiology - physiopathology - therapy
dc.subjectFactor VIII
dc.subjectHemophilia A
dc.subjectHIV infections
dc.subjectMutation
dc.subjectSurvival rate
dc.titleA synopsis of current haemophilia care in Hong Kong
dc.typeArticle
Author Affiliations
  1. Kwong Wah Hospital
  2. Tuen Mun Hospital
  3. Princess Margaret Hospital Hong Kong
  4. Queen Elizabeth Hospital Hong Kong
  5. Prince of Wales Hospital Hong Kong
  6. Pamela Youde Nethersole Eastern Hospital
  7. United Christian Hospital Hong Kong
  8. Queen Mary Hospital Hong Kong
  9. Caritas Medical Centre Hong Kong